The Top 5 Biosimilars Articles for the Week of July 20

July 24, 2020

Here are the top 5 biosimilars articles for the week of July 20, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 20, 2020.

Number 5: Production of the world's first halal biosimilar, which would mean a biologic permissible under Islamic law, would be a feature of expanded commercial biosimilar production in Malaysia, officials involved in the deal said.

Number 4: Wide variation in treatment patterns for Crohn disease is attributable to failures to translate evidence uniformly and cost barriers. Authors of a new report have formulated algorithms to help reduce heterogeneity in treatment of patients.

Number 3: Investigators found that process complexities have created numerous difficulties for biosimilar developers in regulatory filings, but they anticipate that the success rate will improve with experience and improved guidance.

Number 2: India's medical authorities approved Biocon Biologic's itolizumab, an anti-CD6 IgG1 monoclonal antibody, for emergency treatment of cytokine release syndrome in patients with coronavirus disease 2019 (COVID-19).

Number 1: Celltrion Healthcare said an antiviral drug candidate is moving along in trials as a potential treatment for COVID-19.

To read all of these articles and more, visit centerforbiosimilars.com.